Navigation Links
Perrigo Confirms Filing for Generic Version of VANOS(R)
Date:6/9/2008

ALLEGAN, Mich., June 9 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS(R) Cream 0.1%. The Company believes that it is the first to file an ANDA with a Paragraph IV certification against VANOS(R).

VANOS(R) (fluocinonide) Cream 0.1% is a corticosteroid (steroid hormone) approved to relieve the inflammation and itching caused by certain skin conditions that respond to treatment with corticosteroids in patients 12 years of age or older, and had sales of approximately $27 million for the 12 months ended April 2008, as measured by Wolters Kluwer Health.

Perrigo filed its ANDA for Fluocinonide Cream, 0.1% containing a Paragraph IV Certification with the U.S. Food & Drug Administration and notified Medicis Pharmaceutical Corporation, the listed patent holder of its filing. On June 6, 2008, Medicis filed suit alleging patent infringement in the United States District Court for the Western District of Michigan to prevent Perrigo from proceeding with the commercialization of its product. This action formally initiates the patent process under the Hatch-Waxman Act.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet ( http://www.perrigo.com ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
6. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
7. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
8. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
9. Perrigo Company Announces Launch of Clobetasol Propionate Foam
10. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
11. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... They are musicians and librarians, fashion designers and ... fathers, from New England and around the nation. What do they have in common? ... in a beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart Agencies, ... South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing ... a brain tumor. , Jason Bauer and his family are longtime members of ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors ... the securement tape is painful for her. "This is why the co-inventor and I ... she said. , They then created a prototype of the patent-pending AV-AIR, a device ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... The study was published in the prestigious Journal of Veterinary Science & Medical ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John ... by donating a portion of proceeds to two local organizations: North Chicago Animal Control ... & Friends is a team of authorized and trained volunteers who support rescued ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016  Northwest Biotherapeutics (Nasdaq: ... "Company"), a biotechnology company developing DCVax® personalized immune ... the Nasdaq Staff has not accepted the Company,s ... Rules previously reported, and the Company has notified ... Company,s common stock from listing on Nasdaq.  Upon ...
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... Kan. , Dec. 7, 2016   Rx Savings ... West Virginia and its Public Employees Insurance Agency ... members access to their innovative healthcare software, ultimately saving money ... with PEIA and provide its members with access to our ... or a more effective, affordable therapy can be found," says ...
Breaking Medicine Technology: